Angelini Pharma secures exclusive option for Cureverse's Phase 1 Alzheimer's compound, CV-01.
Angelini Pharma has secured an exclusive option agreement with Cureverse Inc. for CV-01, a Phase 1 compound aimed at treating brain health diseases like Alzheimer’s. Angelini will spearhead development and hold global rights outside of specific Asian regions. Cureverse will receive upfront and milestone payments totaling up to $360 million, plus royalties on future sales. This partnership seeks to enhance treatment options for brain health conditions globally.
October 21, 2024
8 Articles